Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.
You may also be interested in...
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End
The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.